NY-CITIGROUP
13.9.2022 20:03:03 CEST | Business Wire | Press release
Citi Private Bank’s Family Office Group today released the results of its 2022 Family Office Survey, capturing the thinking and behaviors of some of the most diverse family offices and ultra-high net worth investors globally. At a time of increasingly broad financial and geopolitical challenges, the report outlines areas of opportunities for potential growth in the year ahead.
Seven predominant themes emerged from the survey: 1) concerns go beyond financial assets, 2) portfolio values declined overall year to date, 3) outlook is positive despite the economic and geopolitical uncertainty, 4) direct investing remains a priority, 5) professionalization of the investment function in family offices continues, 6) readiness to manage family unity and continuity will be key for long-term success, and 7) allocations to sustainable and ESG investments have room to grow.
“Each of our family office clients has a unique need and perspective that helps inform how we can support progress towards their financial goals for generations to come,” says Ida Liu, Global Head of Citi Private Bank. “There is a growing awareness of the dual necessity to prepare wealth for families and families for wealth. And as a trusted partner, Citi Private Bank can help them do that.”
While the top three current economic concerns include inflation, fears of a recession and geopolitical uncertainty, family office executives expressed strong interest in preparing for the future. This includes preserving the value of the family’s assets and preparing the next generation to transition into leadership roles as responsible wealth owners. In fact, leadership successions at the family, family office or trustee levels are among the key transitions that a majority of respondents are expecting to face in the next five years.
“We are thrilled to share this year’s survey highlights, reflecting the urgent need for family offices to plan today for a successful future,” says Hannes Hofmann, the new Global Head of the Family Office Group at Citi Private Bank. “I look forward to working with some of the world’s most diverse and sophisticated family offices.”
Despite the concerns and perhaps a reflection of their sentiment that the market may have bottomed out, there is a high degree of optimism for portfolio returns over the next twelve months, with 80% of the family offices expecting portfolio gains and 62% expecting a 5% or higher increase in portfolio value. As far as asset allocation, public equity represents the lion’s share at 23%, but the attractiveness of real estate and private equity remains, representing 35% of asset allocations combined (20% and 15% respectively).
The 2022 Family Office Survey also found that direct investing remains a primary focus for family offices, with about a third of them allocating between 10% and 20% of their portfolio, while another third allocate more than 30%. Direct investments are split almost evenly between real estate (37%) and operating businesses (33%).
“We were excited to have doubled the number of questions this year to gain more valuable insight into the broad challenges family offices are facing and further understand where they want to go,” says Alexandre Monnier, Global Head of Family Office Services & Network. “In this survey we tried to capture where but also how family offices are investing, such as whether they rely on an investment committee or a board. This information helps further inform our clients on steps their peers are taking to address their needs and meet their goals.”
This year’s survey also showed that the opportunity to translate curiosity about sustainable or ESG investments into action remains significant, as 60% of family offices still have not considered aligning some of their portfolio with these themes or are unsure how they align. Co- or direct investment opportunities, private markets more broadly, and innovative strategies and partnerships demonstrate the greatest potential for ESG-related investments.
This year’s survey was initiated during Citi Private Bank’s seventh annual Family Office Leadership Program held in-person in June 2022 for the first time since the onset of the Covid-19 pandemic. The survey was subsequently released to Citi Private Bank’s global family office clients for input. The survey included over 30 questions aimed at gauging investment sentiment and portfolio actions of clients in the wake of macroeconomic headwinds and market volatility in early 2022. It drew responses from nearly 200 participants, of which 126 were completed and considered for this report.
About Citi Private Bank:
Citi Private Bank is dedicated to serving worldly and wealthy individuals and families, providing customized private banking across borders. With around $500 billion in total client business, the franchise serves clients across 50 cities in over 100 countries. Citi Private Bank helps clients grow and preserve wealth, finance assets, make cash work harder, safeguard assets, preserve legacies, and serve family and family business needs. The firm offers clients products and services covering capital markets, managed investments, portfolio management, trust and estate planning, investment finance, banking and aircraft finance, art advisory and finance, and sports finance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
